Background: The efficacy and safety of a reduced dose of prasugrel versus a standard dose
of ticagrelor in elderly patients or those with a low body weight presenting with an acute …

Dual antiplatelet therapy combining aspirin with a P2Y 12-receptor inhibitor reduces
atherothrombotic events following an acute coronary syndromes (ACS), but the relative …

Background: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in
patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous …

Aims The aim of the present study was to establish the safety and efficacy profile of
prasugrel and ticagrelor in real-life acute coronary syndrome (ACS) patients with renal …

Aims To establish the safety and efficacy of different dual antiplatelet therapy (DAPT)
combinations in patients with acute coronary syndrome (ACS) according to their baseline …

The efficacy and safety of clopidogrel compared with ticagrelor as part of dual antiplatelet
therapy in patients, and in older patients, with acute coronary syndrome is reviewed …

Background To compare effectiveness and safety of clopidogrel, prasugrel, and ticagrelor
among all-comers with ST-segment elevation myocardial infarction (STEMI) and extend the …

Low-dose prasugrel demonstrated a similar effectiveness profile to clopidogrel in East Asian
ACS patients, but its comparison with another new-generation potent P2Y12 inhibitor …

Context Ticagrelor was related to bradycardia in DISPERSE-II trial. This risk has been
integrated into the European risk-management plan, and its use is warned in at-risk patients …

Двойная антитромбоцитарная терапия (ДАТТ), состоящая из аспирина и ингибитора
P2Y12-рецептора тромбоцитов, является золотым стандартом терапии для пациентов …